Has Edgar Hernandez Montalvo, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,470 in general payments to Edgar Hernandez Montalvo, MD across 30 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Edgar Hernandez Montalvo, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Edgar Hernandez Montalvo, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Edgar Hernandez Montalvo, MD

Nephrology · Manati, PRNPI 1033469390

Payments from drug & device makers

$1,470in general payments, 2019–2025

Across 30 payments — averaging $49.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$638
Nxstage Medical, Inc.$410
Mallinckrodt Enterprises LLC$124
Bayer$122
BD$95
Johnson & Johnson$61
plus $20 from 1 others

What the payments were for

Food & beverage$1,470100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	22	$638
Nxstage Medical, Inc.	3	$410
Mallinckrodt Enterprises LLC	1	$124
Bayer	1	$122
BD	1	$95
Johnson & Johnson	1	$61
Calliditas Therapeutics US Inc.	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,470 in reported general payments places this provider in the 40th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$21,714

Medicare patients

Services billed

180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
KerendiaFinerenone	351	$247,295
FarxigaDapagliflozin Propanediol	255	$164,626
Trijardy XrEmpaglifloz/Linaglip/Metformin	200	$126,417
GlyxambiEmpagliflozin/Linagliptin	152	$101,159
JardianceEmpagliflozin	133	$89,189
Sevelamer Carbonate	297	$61,887
VelphoroSucroferric Oxyhydroxide	23	$56,152
Xigduo XrDapaglifloz Propaned/Metformin	72	$45,777
TradjentaLinagliptin	80	$43,619
Lanthanum Carbonate	64	$39,138
Calcium Acetate	283	$27,981
LokelmaSodium Zirconium Cyclosilicate	32	$23,972
OzempicSemaglutide	24	$23,571
EliquisApixaban	34	$17,383
LantusInsulin Glargine,hum.Rec.Anlog	75	$9,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
BayerKerendia	$122	$247,295351 claims
AstraZenecaFarxiga, Lokelma	$638	$188,598287 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Manati

Alexander Borrero-ArveloManati$4K
Keyla Davila MarcanoManati$3K
Lourdes Pena de la VegaManati$3K
Eddie Rodriguez CastroToa Baja$591K
Rafael Burgos CalderonBayamon$394K
Eugenia Galindo RamosCaguas$360K
Jose Cangiano-RiveraSan Juan$300K
Ileana Ocasio MelendezDorado$261K
William Hurtado-SantiagoMayaguez$250K
Jacobo Loyola-TorresCaguas$145K

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →